Journal article 1891 views 214 downloads
Dapagliflozin and renal function. Re: Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Mende CW. Curr Med Res Opin 2017;33:541-551
T. Min,
L. Wali,
D.M. Williams,
E. Plummer,
A. Gurung,
J.W. Stephens,
Jeffrey Stephens 
Current Medical Research and Opinion, Pages: 1 - 2
Swansea University Author:
Jeffrey Stephens
DOI (Published version): 10.1080/03007995.2017.1336432
Abstract
Dapagliflozin and renal function. Re: Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Mende CW. Curr Med Res Opin 2017;33:541-551
| Published in: | Current Medical Research and Opinion |
|---|---|
| ISSN: | 0300-7995 1473-4877 |
| Published: |
2017
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa34694 |
| first_indexed |
2017-07-19T14:18:34Z |
|---|---|
| last_indexed |
2018-02-09T05:25:04Z |
| id |
cronfa34694 |
| recordtype |
SURis |
| fullrecord |
<?xml version="1.0"?><rfc1807><datestamp>2017-08-16T15:44:17.3928257</datestamp><bib-version>v2</bib-version><id>34694</id><entry>2017-07-19</entry><title>Dapagliflozin and renal function. Re: Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Mende CW. Curr Med Res Opin 2017;33:541-551</title><swanseaauthors><author><sid>5219d126f97f8f884bdb622099bd41de</sid><ORCID>0000-0003-2228-086X</ORCID><firstname>Jeffrey</firstname><surname>Stephens</surname><name>Jeffrey Stephens</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2017-07-19</date><deptcode>MEDS</deptcode><abstract/><type>Journal Article</type><journal>Current Medical Research and Opinion</journal><paginationStart>1</paginationStart><paginationEnd>2</paginationEnd><publisher/><issnPrint>0300-7995</issnPrint><issnElectronic>1473-4877</issnElectronic><keywords/><publishedDay>27</publishedDay><publishedMonth>6</publishedMonth><publishedYear>2017</publishedYear><publishedDate>2017-06-27</publishedDate><doi>10.1080/03007995.2017.1336432</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2017-08-16T15:44:17.3928257</lastEdited><Created>2017-07-19T10:16:51.5641649</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>T.</firstname><surname>Min</surname><order>1</order></author><author><firstname>L.</firstname><surname>Wali</surname><order>2</order></author><author><firstname>D.M.</firstname><surname>Williams</surname><order>3</order></author><author><firstname>E.</firstname><surname>Plummer</surname><order>4</order></author><author><firstname>A.</firstname><surname>Gurung</surname><order>5</order></author><author><firstname>J.W.</firstname><surname>Stephens</surname><order>6</order></author><author><firstname>Jeffrey</firstname><surname>Stephens</surname><orcid>0000-0003-2228-086X</orcid><order>7</order></author></authors><documents><document><filename>0034694-16082017153748.pdf</filename><originalFilename>34694.pdf</originalFilename><uploaded>2017-08-16T15:37:48.9500000</uploaded><type>Output</type><contentLength>306136</contentLength><contentType>application/pdf</contentType><version>Accepted Manuscript</version><cronfaStatus>true</cronfaStatus><embargoDate>2018-05-31T00:00:00.0000000</embargoDate><documentNotes>12 month embargo.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language></document></documents><OutputDurs/></rfc1807> |
| spelling |
2017-08-16T15:44:17.3928257 v2 34694 2017-07-19 Dapagliflozin and renal function. Re: Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Mende CW. Curr Med Res Opin 2017;33:541-551 5219d126f97f8f884bdb622099bd41de 0000-0003-2228-086X Jeffrey Stephens Jeffrey Stephens true false 2017-07-19 MEDS Journal Article Current Medical Research and Opinion 1 2 0300-7995 1473-4877 27 6 2017 2017-06-27 10.1080/03007995.2017.1336432 COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University 2017-08-16T15:44:17.3928257 2017-07-19T10:16:51.5641649 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine T. Min 1 L. Wali 2 D.M. Williams 3 E. Plummer 4 A. Gurung 5 J.W. Stephens 6 Jeffrey Stephens 0000-0003-2228-086X 7 0034694-16082017153748.pdf 34694.pdf 2017-08-16T15:37:48.9500000 Output 306136 application/pdf Accepted Manuscript true 2018-05-31T00:00:00.0000000 12 month embargo. true eng |
| title |
Dapagliflozin and renal function. Re: Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Mende CW. Curr Med Res Opin 2017;33:541-551 |
| spellingShingle |
Dapagliflozin and renal function. Re: Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Mende CW. Curr Med Res Opin 2017;33:541-551 Jeffrey Stephens |
| title_short |
Dapagliflozin and renal function. Re: Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Mende CW. Curr Med Res Opin 2017;33:541-551 |
| title_full |
Dapagliflozin and renal function. Re: Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Mende CW. Curr Med Res Opin 2017;33:541-551 |
| title_fullStr |
Dapagliflozin and renal function. Re: Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Mende CW. Curr Med Res Opin 2017;33:541-551 |
| title_full_unstemmed |
Dapagliflozin and renal function. Re: Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Mende CW. Curr Med Res Opin 2017;33:541-551 |
| title_sort |
Dapagliflozin and renal function. Re: Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Mende CW. Curr Med Res Opin 2017;33:541-551 |
| author_id_str_mv |
5219d126f97f8f884bdb622099bd41de |
| author_id_fullname_str_mv |
5219d126f97f8f884bdb622099bd41de_***_Jeffrey Stephens |
| author |
Jeffrey Stephens |
| author2 |
T. Min L. Wali D.M. Williams E. Plummer A. Gurung J.W. Stephens Jeffrey Stephens |
| format |
Journal article |
| container_title |
Current Medical Research and Opinion |
| container_start_page |
1 |
| publishDate |
2017 |
| institution |
Swansea University |
| issn |
0300-7995 1473-4877 |
| doi_str_mv |
10.1080/03007995.2017.1336432 |
| college_str |
Faculty of Medicine, Health and Life Sciences |
| hierarchytype |
|
| hierarchy_top_id |
facultyofmedicinehealthandlifesciences |
| hierarchy_top_title |
Faculty of Medicine, Health and Life Sciences |
| hierarchy_parent_id |
facultyofmedicinehealthandlifesciences |
| hierarchy_parent_title |
Faculty of Medicine, Health and Life Sciences |
| department_str |
Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine |
| document_store_str |
1 |
| active_str |
0 |
| published_date |
2017-06-27T04:09:42Z |
| _version_ |
1856891134075207680 |
| score |
11.096068 |